Multicell Techs Inc (MCET)
Multicell Techs Inc is a common stock listing on OTC Markets tied to MultiCell Technologies, Inc., a biopharmaceutical company focused on developing therapeutics and discovery tools for neurological disorders, hepatic disease, cancer, and selected cardiovascular applications. Its pipeline includes MCT-125, a Phase II candidate being studied for primary multiple sclerosis-related fatigue, along with MCT-465 and MCT-485, both of which are at earlier development stages and are being evaluated for cancer-related applications. The company is also developing Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel use. MultiCell Technologies has license agreements with Corning Incorporated and Pfizer Inc. The company was previously known as Exten Industries, Inc. and adopted its current name in April 2004. It was founded in 1962 and is based in Woonsocket, Rhode Island.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MCET
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
5 K
|
—
|
—
|
—
|
—
|
—
|
—
|
